Substances Generally Recognized as Safe
Docket No. FDA-2025-N-3262. RIN 0910-AJ02
9 Active Regulatory Applications and 11+ US Market Entry Projects
Advanced Food Regulation (“AFR”) welcomes the opportunity to comment on the Food and Drug Administration’s proposed amendments to the regulatory framework for substances Generally Recognized as Safe (“GRAS”).
International Food Regulatory Consultancy Supporting US Market Access
AFR is an international food regulatory consultancy advising ingredient manufacturers, food businesses and biotechnology companies on regulatory market access in the United States and other major jurisdictions. At the date of this submission, AFR is supporting nine active regulatory applications and more than eleven businesses pursuing US market entry strategies across various regulated food types and products, including matters involving the GRAS framework. Our comments are therefore informed by current practical experience of the scientific, regulatory and commercial considerations encountered by businesses seeking to place innovative food ingredients on the US market.
AFR supports the principle of mandatory Notification. Greater transparency should provide the FDA with improved visibility of substances entering the food supply, strengthen confidence in the GRAS framework and provide enhanced consumer protection. Responsible businesses investing in the development of new food ingredients should equally be capable of demonstrating the scientific basis upon which a currently self-affirmed GRAS conclusion has been reached.
The change from voluntary to mandatory Notification does, however, alter the practical significance of the Notification procedure. Interaction with FDA will become an unavoidable part of the GRAS pathway for substances within the scope of the proposed requirement. The clarity, proportionality and predictability of that process will therefore become considerably more important.
A Defined FDA Filing Period Without Additional Substantive Review
AFR supports the introduction of a defined period for the FDA’s initial assessment of whether a submission should be filed as a GRAS Notice. We consider, however, that the proposed 45-day period should operate principally as an administrative completeness assessment and should not develop into an additional substantive review stage.
Where the FDA decides that a submission cannot be filed, the reasons should be communicated with sufficient specificity to allow deficiencies to be addressed efficiently. Considerable scientific and financial investment may have been made before a GRAS Notice reaches the FDA and uncertainty at the point of filing can affect manufacturing, investment and commercial decisions as well as the regulatory programme itself.
AFR recognises that mandatory Notification is likely to increase the number of submissions received by the FDA and that complex Notices require appropriate time for scientific evaluation. Nevertheless, the possibility of substantially extended evaluation periods following filing creates uncertainty for businesses seeking to plan investment, manufacturing and US commercial activity.
The introduction of mandatory Notification should therefore be accompanied by sufficient FDA resource to ensure that extended review periods remain the exception rather than becoming a routine consequence of increased submission volumes. Where an extension is necessary, early communication concerning the substantive issues requiring further consideration would assist Notifiers in managing both the regulatory process and legitimate commercial planning.
This is particularly important because mandatory Notification should not be confused with pre-market authorisation. The GRAS conclusion remains the Notifier’s conclusion and the proposed framework does not require a business to await the FDA’s response before introducing the substance into interstate commerce. Clear communication about the respective responsibilities of the FDA and the Notifier will therefore remain important under the new framework.
International Businesses and Access to the US Market
AFR particularly welcomes the FDA’s recognition of the substantial participation of foreign businesses in the GRAS Notification programme. The United States remains an important market for food and ingredient innovation developed elsewhere in the world, and a significant proportion of AFR’s work involves assisting businesses to understand and satisfy regulatory requirements across different jurisdictions.
Mandatory Notification should not present a difficulty for responsible international businesses capable of substantiating the safety of their ingredients. It will, however, make clear and accessible FDA requirements increasingly important for businesses unfamiliar with US regulatory procedures.
AFR supports the proposed requirement for accurate and complete English translations where foreign-language material is relied upon in a GRAS Notice. Further guidance would nevertheless be helpful concerning the extent of this requirement, particularly where a Notice relies upon extensive scientific literature or historical evidence originating outside the United States. The FDA should have full access to material which evidences the safety assessment, without imposing unnecessary translation costs for information of limited relevance.
We also welcome the proposed clarification concerning conclusions based upon common use in food outside the United States before 1958. International historical evidence can be valuable but may differ considerably in its nature, accessibility and quality. Guidance concerning the evidence which the FDA considers sufficient to establish the nature, extent and continuity of historical use would provide useful regulatory certainty.
Scientific Requirements and Regulatory Burden
AFR agrees that GRAS status must rest upon a robust scientific foundation and that general recognition cannot compensate for inadequate evidence of safety. Increased transparency should reinforce this principle.
It is important, however, to distinguish the administrative burden of preparing and submitting a GRAS Notice from the scientific and regulatory work necessary to reach a defensible GRAS conclusion.
In practice, this may require detailed assessment of identity and composition, manufacturing methodology, specifications, analytical methods, stability, intended conditions of use, dietary exposure and toxicological evidence. For newer ingredients, particularly those arising from biotechnology, fermentation and other innovative manufacturing processes, initial regulatory assessment may identify data gaps requiring additional analytical or safety studies before a GRAS conclusion can responsibly be reached.
The resources required can therefore be considerably greater than the administrative time involved in assembling and submitting the Notice itself. This distinction should be reflected in the FDA’s assessment of regulatory burden, particularly in relation to smaller innovative businesses.
This is not an argument for reducing the scientific standard. Greater clarity as to the FDA’s evidential expectations can itself reduce unnecessary regulatory burden. Businesses that understand those expectations at an early stage are better able to identify data gaps, commission appropriate studies and avoid expenditure on work that does not adequately address the relevant safety question.
Existing GRAS Conclusions and Transition
AFR supports a proportionate transitional mechanism for substances already introduced into interstate commerce on the basis of an independent GRAS conclusion. Businesses that have acted legitimately under the existing framework should have a practical route into the new system without unnecessary duplication of scientific work already undertaken.
The FDA’s proposed time limited streamlined submission mechanism is therefore welcome. Its implementation should nevertheless provide clarity concerning the evidence necessary to demonstrate that a substance and its relevant conditions of use qualify for the transitional pathway.
There is also a broader practical issue concerning subsequent changes to manufacturing processes, specifications or conditions of use. Food ingredients and their manufacturing processes evolve. Clear guidance would assist businesses in determining when a change remains within the scope of an existing GRAS conclusion or Notification and when it is sufficiently material to require further assessment or Notification.
A Proportionate Pathway for Changes to Reviewed GRAS Substances
AFR considers that there is scope for a more proportionate Notification procedure where the FDA has previously evaluated a GRAS Notice and issued a no questions letter, but a subsequent change raises the question of whether the existing GRAS conclusion continues to apply.
A change in manufacturing methodology, for example, may have no material effect upon safety, equally it may alter composition, impurities or other characteristics sufficiently to require further assessment. The regulatory question should therefore be the significance of the change rather than the fact that a change has occurred.
AFR suggests that the FDA consider an abbreviated Notification pathway under which a Notifier could identify the previous GRAS Notice, describe precisely what has changed, provide a reasoned assessment of the effect of that change upon identity, composition, exposure and safety as applicable and submit the additional scientific evidence necessary to demonstrate that the previous GRAS conclusion remains supportable.
Such a procedure should not be available where a change materially alters the substance or introduces safety questions requiring a complete reassessment. In those circumstances, a full GRAS Notice would remain appropriate. Where the underlying scientific information has already been provided to and evaluated by the FDA, however, requiring substantial duplication of that material creates additional work for both the Notifier and the Agency without necessarily improving the quality of the safety assessment.
A defined abbreviated pathway would preserve the scientific standard while allowing regulatory resources to be directed towards the matters that have actually changed. It would also provide businesses with a clearer framework for managing manufacturing improvements, specification changes and changes to conditions of use following FDA evaluation of a GRAS Notice.
Conclusion
AFR supports the FDA’s objective of increasing transparency and regulatory oversight of substances relied upon as GRAS. The proposed move to mandatory Notification represents a significant change to the operation of the GRAS framework and should be implemented in a manner that combines appropriate scientific scrutiny with a clear, proportionate and predictable regulatory process.
In our experience, businesses developing innovative food ingredients are prepared to invest substantially in demonstrating safety. What they require in return is sufficient clarity to understand the scientific standard they are expected to meet and sufficient predictability to plan regulatory and commercial decisions responsibly.
The proposed rule presents an opportunity not simply to increase the FDA’s visibility of GRAS conclusions, but to strengthen confidence in the GRAS framework itself. A system combining rigorous scientific standards with clear evidential expectations, proportionate transitional arrangements and efficient FDA review should protect consumers while continuing to facilitate responsible food innovation and access to the US market.
Advanced Food Regulation appreciates the opportunity to contribute to the FDA’s consideration of these important reforms.
Steve Oliver
Matt Lawson
Co-Founders


